The VRONI study has provided significant insights into the effectiveness of pediatric FH screening. Familial Hypercholesterolaemia (FH) is a common genetic disorder. It causes high LDL cholesterol from birth, leading to early cardiovascular disease. This study, conducted in Southern Germany, evaluated a two-step approach to identify affected children. Consequently, the findings support the call for universal screening programs to prevent premature heart disease.

Implementing Effective Pediatric FH Screening

The research team invited over 480 pediatricians in Bavaria to offer screening to children aged 5 to 15. Specifically, the process involved taking 0.2 mL of blood from a fingertip. If the low-density lipoprotein cholesterol (LDL-C) reached 3.36 mmol/L (130 mg/dL) or higher, the sample underwent genetic testing. This focused panel covered common variants and sequenced relevant genes. Furthermore, the study demonstrated that this biochemical-first approach is highly feasible in routine pediatric practice.

Out of 25,431 children screened, researchers found 1,689 with elevated LDL-C levels. Among these, they identified pathogenic variants in 283 individuals. Interestingly, the prevalence of FH-causing variants increased significantly with higher LDL-C concentrations. For instance, the positive rate was 78.6% in children with LDL-C above 5.17 mmol/L. After adjusting for bias, the predicted prevalence was 1 in 163. This figure is notably higher than the historical estimate of 1 in 250. Additionally, sequencing candidate genes proved more effective than using a focused variant panel alone.

Clinical Relevance for Healthcare Providers

These findings emphasize that early detection is crucial for managing FH. In India, where premature coronary artery disease is rising, universal screening could save many lives. Furthermore, the two-step method minimizes patient burden while ensuring high diagnostic accuracy. Therefore, pediatricians should consider biochemical screening as a reliable first step for identifying at-risk children.

FAQs

At what age should pediatric FH screening begin?

Most guidelines, including the VRONI study, suggest screening children between ages 5 and 15. However, universal screening is often recommended between ages 9 and 11 to capture most cases before puberty affects lipid levels.

Why is genetic testing necessary after a high LDL-C result?

Genetic testing confirms the diagnosis of monogenic FH. It distinguishes genetic cases from multifactorial dyslipidemia. Moreover, identifying a specific variant allows for cascade screening of other family members.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional opinion. Readers should consult with a qualified healthcare professional for medical diagnosis or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Schmieder RS et al. Genetic screening of children for familial hypercholesterolaemia: the VRONI study. Eur Heart J. 2026 Jun 16. doi: undefined. PMID: 42301736.

Flyer JN et al. State-of-the-art review: The value of leveraging evidence and data (LEAD) in pediatric screening for familial hypercholesterolemia. Am J Prev Cardiol. 2025 Aug 22;23:101262.

Barde AK et al. Indian prevalence of familial hypercholesterolemia demystified by applying Dutch lipid clinic network criteria. Int J Adv Med. 2022 Nov;9(11).